Correction: Nkarta reports financial results and operating highlights for the second quarter of 2024

• Enrollment is expected to begin in late 2024 in the second clinical trial of NKX019 in autoimmune diseases, Ntrust-2, for the treatment of systemic sclerosis, myositis and vasculitis
• Preliminary clinical data from clinical trials of Ntrust-1 and Ntrust-2 planned for 2025
• Cash balance of $426.7 million as of June 30, 2024, including cash, cash equivalents and investments, which is expected to fund operations through the end of 2027

This press release has been updated to reflect the correct dosing schedule for the investigator-sponsored clinical trial of NKX019. As previously announced, patients participating in this trial will receive three doses of NKX019 on days 0, 7, and 14.

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing specially developed natural killer (NK) cell therapies, today announced financial results for the second quarter ended June 30, 2024.